


HEALTH INFORMATION TECHNOLOGY

Findings and Report Viewers All reporting modules

ACV 8.0

doc v1

Study findings are reviewed in either the *Findings viewer* or *Report viewer*. The written content is identical between the two viewers unless something has specifically configured to be excluded from the *Report viewer*. Although the example below uses an echocardiography report, the process is the same for all of ASCEND's reporting modules.





The *Findings viewer* is a concise view of the recorded findings, allowing more space for data entry by omitting the report header and diagrams, and by showing tables in a closed format.

Study Measurements Calculations Display Findings Report History - transthoracic conf(d) LV function (conf(d) Allergies, c Nitrates asse LV function (conf(d) Allergies, c Past medical history > Prior MI on date > Nitrates Prior Cononary stering Prior cononary stering Study data : Prior cononary stering > Study data : Prior CABG Allergies, c Nitrates Prior CabG on date > Prior CABG on date > Prior CABG on date > Prior CaBG on date > Prior CABG on date > Prior CABG on date > Prior CaBG on date > Prior CaBG on date > Prior CaBG on date > Prior CaBG on date > Prior CaBG on date > Prior CaBG on date > Prior CaBG on date > Prior CaBG on date > Transthoracic chocardiography was performed. Image quality was adequate. Scanning was performed from the parasternal	S Un	ido 🙋	Redo ? Help 🔆 Options	Q LEARN	-		
cont'd) LV function (cont'd) Allergies, c isase Evaluate pre-chemotherapy \ Nitrates isase Evaluate post-chemotherapy \ Nitrates Past medical history > Image: Cont'd) Nitrates Prior MI on date Nitrates Image: Cont'd) Image: Cont'd) MI Nitrates Patient status, risk factors Image: Cont'd) Prior conary stent on date Nitrates Prior conary stent on date Nitrates Prior CABG Prior CABG Prior CABG Prior CABG Nitrates Prior CABG Prior canaplant on date Prior canaplant on date Prior call on date Procedure narrative Transhorac		n O Index		ents Calculation	is Dia 🚺	Findings Report	
cont'd) LV function (cont'd) Allergries. is asse Evaluate post-chemotherapy ? is asse Past medical history > Prior MI on date ? MI ? Prior cath on date ? Prior cath on date ? Prior cath on date ? Prior cabG ? Prior CABG ? Prior CABG ? Prior CABG ate ?	Histo	ry - tran	sthoracic			-	~
Weight: 200 lb. @bMI: 28.8 kg/m². @BSA: 2.14 m². @92 bpm. @150/88 @ Prior cath on date Prior cath on date Prior CABG Prior CABG on date Prior transplant on date Prior transpla			Evaluate pre-chemotherapy Evaluate post-chemotherapy Past medical history > Prior MI on date	× N		normal. The estimated ejection fraction is 55-65%.	
e Patient status, risk factors ▶ □ e New Family history of CAD □ ertension Smoking □ Hypertension □ Hypertension □ Diabetes mellitus □ □ Aortic valve □ □ Dyslipidemia □ □ The valve is structurally normal. The valve is trileaflet. □Cusp separation is normal. □ Allergies, diet, and meds ▶ □ Systemic arteries □ Beta blockers □ Scroll for additional content → □ Mitral valve □ Mitral valve □		~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Prior cath on date Prior coronary stent on date Prior CABG Prior CABG on date Prior transplant on date	8) 8) 8) 8)		Weight: 200 lb. ■ BMI: 28.8 kg/m². ■ BSA: 2.14 m². ■92 bpm. ■150/88 ■ Transthoracic echocardiography. ■ M-mode, complete 2D, and complete spectral Doppler. ■ The risks were explained to the patient's next of kin and informed consent was obtained. ■ Outpatient. ■ Routine. ■ Echo laboratory. ■ Procedure room # 3. ■ The patient tolerated the procedure well. ■ Procedure narrative ■ Transthoracic echocardiography was performed. Image quality was adequate. Scanning	
Family history of CAD	<u>م</u>	*	Patient status, risk factors	N E			
Diabetes mellitus □ Dyslipidemia □ Allergies, diet, and meds > □ □ Beta blockers □ Calcium channel blockers □ Scroll for additional content → Mitral valve □	e ► ertensio		Family history of CAD Smoking			estimated ejection fraction is 55-65%. ^{Sum} ≡ Wall motion is normal; there are no regional wall motion abnormalities. ^{Sum} ≡ Wall motion score: 1.00. ≡	
Calcium channel blockers Scroll for additional content → Aortic root: The aortic root is normal-sized. ■ Mitral valve ■	ension		Dyslipidemia			The valve is structurally normal. The valve is trileaflet.	
		*			•	Aortic root: The aortic root is normal-sized.	~
	<	_			>		




The *Report viewer* displays the findings as they appear in the final report.

S Un	do) 🙋 F	Redo 🤶 Help 🔆 Options	Q LEARN		
Search	O Index	History Study Measurem	ents Calculations Dia	Þ	Findings Report
Histo	ry - trans	sthoracic			ASCEND General Hospital 1234 Main St. Anywhere, USA 02345
cont'd) ease		LV function (cont'd) Evaluate pre-chemotherapy Evaluate post-chemotherapy		` ^	
		Past medical history → 🗉			M-mode, complete 2D, and complete spectral Doppler
1	2	Prior MI on date MI	45 5		Patient: Ralph Julius Lowell Study date: 08/06/2018Height: 177.8 cm MRN: #648379 (MRN) Birth date: 01/27/1943 (70 in) Accession: #698aod964 Age: 75 year(s) Weight: 90.9 kg (200 lb)
ation	* * *	Labs, prior procedures → Prior cath on date Prior coronary stent on date Prior CABG Prior CABG on date	2+ 2+ 2+ 2		Patient location: Birth M BSA: 2.14 m² Study status: Routine gender: BMI: 28.8 kg/m² Facility: East Campus Patient Outpatient HR: 92 bpm Summary: 1. Left ventricle: The cavity size is normal. Wall thickness is normal. Image: Systolic function is
tion e	* * *	Prior transplant on date Abnormal ECG Patient status, risk factors	2		normal. The estimated ejection fraction is 55-65%. I Wall motion is normal; there are no regional wall motion abnormalities. 2. New summary item Recommendations: New recommendation
e 🕨	New	Family history of CAD			Prior history: <u>Risk factors:</u> The patient is a former tobacco user.
ertensio ase ension m	n 🗌	Smoking Hypertension Diabetes mellitus Dyslipidemia			Study data: <u>Race:</u> Black. ■ <u>Study status:</u> Routine. ■ <u>Study location:</u> Echo laboratory. ■ Procedure room # 3. ■ <u>Consent:</u> The risks were explained to the patient's next of kin and informed consent was obtained. ■ <u>Procedure:</u> Transthoracic echocardiography was performed. Image quality was adequate. Scanning was performed from the parasternal, apical, and subcostal acoustic windows. ■ <u>Study completion:</u> The patient tolerated the
	8	Allergies, diet, and meds →			procedure well.
	*	Beta blockers Calcium channel blockers		~	Left ventricle: The cavity size is normal. Wall thickness is normal. Sum Systolic function is normal. The estimated ejection fraction is 55-65%. Sum Wall motion is normal; there
<	٠		Scroll for additional content -	•	are no regional wall motion abnormalities. ^{Sum}



Left-clicking on a finding in either viewer will sync directly to the location of that finding in the data entry form.



To edit a sentence, right click on the finding in either viewer to display a menu with editing options.

S Undo	nedo 🖉	? Help 💥 Options 🔎 l	LEARN			
O Search	O Index	History Study Measurements	Calculations	Dia ▶	Findings Report	
History -	transthor	acic			Summary 🗏	~
ons (cont'd) Il disease /thm		LV function (cont'd) Evaluate pre-chemotherapy Evaluate post-chemotherapy Past medical history ► Prior MI on date	2	Allers 🔨	Left ventricle: The cavity size is normal. Wall thickness is normal.	
ECG	8	MI	>		Study data E × Delete fragment	
lation er rrest urgitation nosis urgitation	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Labs, prior procedures ► Prior cath on date Prior coronary stent on date Prior CABG Prior CABG on date Prior transplant on date Abnormal ECG	- * * * * * * * * * * * * *		Patient is 75 year(s) old. Patient Black. Birth gender: male. He Weight: 200 lb. BMI: 28.8 kg/m ² Transthoracic echocardiography. Doppler. The risks were explain obtained. Outpatient. Routine patient tolerated the procedure well. Procedure narrative Transthoracic echocardiography was performed. Image quality was adequate. Scanning was performed from the parasternal, apical, and subcostal acoustic windows.	
nosis valve	2	Patient status, risk factors	· √ ■		Left ventricle	
sease ► y hypertensio	New	Family history of CAD Smoking Hypertension			The cavity size is normal. Wall thickness is normal. ^{Sumy}	
disease ypertension section		Diabetes mellitus Dyslipidemia Allergies, diet, and meds ►			Aortic valve □ The valve is structurally normal. The valve is trileaflet. □Cusp separation is normal. Transvalvular velocity is within the normal range. There is no stenosis. □ Systemic arteries □	
	*	Beta blockers Calcium channel blockers		U	Aortic root: The aortic root is normal-sized.	
<	\$		or additional con	itent →	Mitral valve 🗉	~




Selecting *Edit sentence* results in the display of a sentence editor which supports the ability to enter free text to modify the sentence. Click the *Done* button to save the edits and insert the sentence into the report.

I diseas <i>rthm</i> ECG lation		
Search Histo I diseas Rthm ECG Iation		
	Ŷ	
I diseas <i>rthm</i> ECG lation		hormal; there are
thm ECG lation		
ECG lation		
lation lation		08/06/2018. 🗉
		eight: 90.9 kg. 88
		e spectral rmed consent was
		om # 3. 🗏 The
urgitatio		quate. Scanning
Tobacco		ows. 🗉
Descri Tob		ion is normal. The
Exp		e are no regional
Ciga		
Dail		n is normal. 🗉
Paci Paci		There is no
Quit Done Cancel		
 Sentence edits should <u>not</u> change The basic meaning of a finding Any numeric values or units Such changes should be made using the data entry forms. 		
Scroll for additional content → Scroll for additional content → Scroll for additional content →	🗉 There i	svalvular velocity is no significant

A S C E N D

Left-clicking the note icon next to a sentence opens a text box allowing the entry of free text.





Right-clicking on a finding also provides access to controls for deleting a fragment of the finding, the entire finding, or adding the finding to the *Summary* that appears as a list at the top of the report.

			EARN		
Q Search Ir	O Index	History Study Measurements	Calculations	Dia 🕨	Findings Report
History - t	transthora	acic			Doppler. The risks were explained to the patient's next of kin and informed consent was obtained. Outpatient. Routine. Echo laboratory. Procedure room # 3. The
ons (cont'd) I disease		LV function (cont'd) Evaluate pre-chemotherapy Evaluate post-chemotherapy	-	Allerc Allerc	
rthm		Past medical history >			was performed from the parasternal, apical, and subcostal acoustic windows.
ECG lation	2 2	Prior MI on date MI	\$) \$		The cavity size is normal. Wall thickness is normal. ^{Sumy} Systolic function is normal. The estimated ejection fraction is 55-65%. ^{Sumy} Sum
er rrest e urgitation nosis urgitation nosis	~ ~ ~ ~ ~ ~ ~ ~ ~	Labs, prior procedures → Prior cath on date Prior coronary stent on date Prior CABG Prior CABG on date Prior transplant on date Abnormal ECG	■ * * * * * * * * *		wall motion abnormalities. ^{Sumy}
valve	<u>`</u>	Patient status, risk factors >	· =		The valve is structurally normal. E Leaflet separation is normal. Transvalvular velocity is within the normal ranges no significant
sease ► y hypertensior disease ypertension section	Newn	Family history of CAD Smoking Hypertension Diabetes mellitus Dyslipidemia			regurgitation. × Delete fragment × Delete finding × Delete finding The atrium is normal in s Surry Set Summary Right ventricle I Enter free-text note before finding I Enter free-text note before finding
	2 2	Allergies, diet, and meds ► Beta blockers			Pulmonic valve
<	\$	Calcium channel blockers Scroll fr	or additional cor	ntent →	Pulmonary artery I The main pulmonary artery is normal-sized. I The tricuspid jet envelope definition is



The numbered findings in the *Summary* section of the report can be reordered by means of a drag and drop action. Hovering over the number associated with the finding will be highlight the finding in a dotted box and the mouse cursor will change to a double-headed vertical arrow. Click and drag up or down to the desired position in the *Summary list*.

S Undo	nedo	💡 Help 💥 Options 🔎 L	EARN	•		
Q Search	O Index	History Study Measurements	Calculations	Dia 🕨	Findings Report	
History -	transthora	acic			Summary 🗏	~
ons (cont'd) I disease		LV function (cont'd) Evaluate pre-chemotherapy Evaluate post-chemotherapy	-	Allerc Nitra	 Left ventricle: The cavity size is normal. Wall thickness is normal. Systolic function is normal. The estimated ejection fraction is 55-65%. Wall motion is normal; there are no regional wall motion abnormalities. Mitral valve: The valve is structurally normal. New summary item 	
<i>rthm</i> ECG lation		Past medical history > Prior MI on date MI	= * *		Patient status, risk factors E Former tobacco user. E Study data E	
er rrest se urgitation	2 2	Labs, prior procedures > Prior cath on date Prior coronary stent on date Prior CABG Prior CABG on date	27 27 27 27 27		Patient is 75 year(s) old. Patient birthdate: 01/27/1943. Study date: 08/06/2018. Black. Birth gender: male. Height: 177.8 cm. Height: 70 in. Weight: 90.9 kg. Weight: 200 lb. BMI: 28.8 kg/m ² . BSA: 2.14 m ² . Height: 70 in. Weight: 90.9 kg. Transthoracic echocardiography. M-mode, complete 2D, and complete spectral Doppler. The risks were explained to the patient's next of kin and informed consent was obtained. Outpatient. Routine. Echo laboratory. Procedure room # 3. The patient tolerated the procedure well.	
nosis urgitation nosis	*	Prior transplant on date Abnormal ECG	\$) \$		Procedure narrative Transthoracic echocardiography was performed. Image quality was adequate. Scanning	
valve	×	Patient status, risk factors	v 🗉		was performed from the parasternal, apical, and subcostal acoustic windows. Left ventricle	
sease ► y hypertensi disease ypertension section	New on	Family history of CAD Smoking Hypertension Diabetes mellitus Dyslipidemia			The cavity size is normal. Wall thickness is normal. Sum Systolic function is normal. The estimated ejection fraction is 55-65%. Sum Sum Wall motion is normal; there are no regional wall motion abnormalities. Sum Sum Wall motion score: 1.00.	*
	2	Allergies, diet, and meds > Beta blockers Calcium channel blockers Scroll fo	r additional co	ntent →	Transvalvular velocity is within the normal range. There is no stenosis. ☐ There is no regurgitation.	~
				/	Mitral valvo 🗏	
\bigwedge	ASCEN	D			8.0 v2	1



HEALTH INFORMATION TECHNOLOGY

www.ascendhit.com Phone (Toll Free): 844-413-2610 Email: information@ascendhit.com

© 2021 ASCEND HIT LLC. All Rights Reserved. The distribution, publication, modification, or reproduction of this document is strictly prohibited without the prior written consent of ASCEND HIT LLC.